POS-604 MIDDLE MOLECULE CLEARANCE & EXPANDED DIALYSIS: WHAT IS THE IMPACT ON PATIENT-REPORTED SYMPTOM BURDE, THROUGH THE LENS OF THE LONDON EVALUATION OF ILLNESS (LEVIL)
J. PENNY
Kidney International Reports · 2021
doi:10.1016/j.ekir.2021.03.633 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Traditionally used high flux (HF) dialyzers are incapable of clearing toxins of larger middle molecular weight, which are mainly responsible for chronic systemic inflammation, cardiovascular adversity, and poor clinical outcomes in the hemodialysis (HD) population. The recent advent of medium cut-off dialyzers (MCO)–termed expanded dialysis (HDx), have been proven to clear these hard-to-reach toxins while selectively retaining valuable proteins–a step in the right direction as we strive to improve patient care.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.